Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myelodysplastic Syndromes × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

venetoclax 17 Azacitidine 16 fludarabine 11 fludarabine phosphate 8 Cyclophosphamide 8 Biopsy 8 Whole-Body Irradiation 7 Specimen Handling 7 Decitabine 7 Injections 6 Granulocyte Colony-Stimulating Factor 6 Busulfan 6 decitabine and cedazuridine drug combination 5 Stem Cell Transplantation 5 Melphalan 5 Cytarabine 5 Mycophenolic Acid 4 Filgrastim 4 olutasidenib 3 X-Rays 3 Thiotepa 3 Mesna 3 Cyclosporins 3 Cyclosporine 3 Cladribine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 ruxolitinib 2 posaconazole 2 pevonedistat 2 enasidenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡